BindingDB logo
myBDB logout

79 articles for thisTarget

The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
28085275 53 Structure-Based Design of Macrocyclic Factor XIa Inhibitors: Discovery of the Macrocyclic Amide Linker.EBI Bristol-Myers Squibb Company
28197309 40 Structure-Guided Design of Novel, Potent, and Selective Macrocyclic Plasma Kallikrein Inhibitors.EBI Global Blood Therapeutics
27994741 48 Discovery of Phenylglycine Lactams as Potent Neutral Factor VIIa Inhibitors.EBI Bristol-Myers Squibb R&D
27739691 7 Fragment-to-Lead Medicinal Chemistry Publications in 2015.EBI Astex Pharmaceuticals
27455395 66 Discovery of a Highly Potent, Selective, and Orally Bioavailable Macrocyclic Inhibitor of Blood Coagulation Factor VIIa-Tissue Factor Complex.EBI Bristol-Myers Squibb R&D
27015008 51 Atropisomer Control in Macrocyclic Factor VIIa Inhibitors.EBI Bristol-Myers Squibb Research& Development
27073051 71 Orally bioavailable pyridine and pyrimidine-based Factor XIa inhibitors: Discovery of the methyl N-phenyl carbamate P2 prime group.EBI Bristol-Myers Squibb Company
26704266 80 Novel phenylalanine derived diamides as Factor XIa inhibitors.EBI Bristol-Myers Squibb Company
26005539 23 Discovery of a Potent Parenterally Administered Factor XIa Inhibitor with Hydroxyquinolin-2(1H)-one as the P2' Moiety.EBI Bristol-Myers Squibb
25990761 66 Novel Small Molecule Inhibitors of Activated Thrombin Activatable Fibrinolysis Inhibitor (TAFIa) from Natural Product Anabaenopeptin.EBI Institute for Infection Research
25728130 79 Structure-based design of inhibitors of coagulation factor XIa with novel P1 moieties.EBI Bristol-Myers Squibb Company
24951330 25 Orally bioavailable factor Xa inhibitors containing alpha-substituted gem-dimethyl P4 moieties.EBI Bristol-Myers Squibb Company
25517413 1 Total synthesis of clavatadine A.EBI Central Washington University
25453807 13 A simple, general approach of allosteric coagulation enzyme inhibition through monosulfated hydrophobic scaffolds.EBI Virginia Commonwealth University
25405503 109 Phenylimidazoles as potent and selective inhibitors of coagulation factor XIa with in vivo antithrombotic activity.EBI Bristol-Myers Squibb
25179681 81 Design, synthesis, and structure-activity and structure-pharmacokinetic relationship studies of novel [6,6,5] tricyclic fused oxazolidinones leading to the discovery of a potent, selective, and orally bioavailable FXa inhibitor.EBI Chinese Academy of Sciences
24666186 15 Allosteric inhibition of human factor XIa: discovery of monosulfated benzofurans as a class of promising inhibitors.EBI Virginia Commonwealth University
24405333 69 Tetrahydroquinoline derivatives as potent and selective factor XIa inhibitors.EBI Bristol-Myers Squibb Company
24418773 61 Design, synthesis, and SAR of a series of activated protein C (APC) inhibitors with selectivity against thrombin for the treatment of haemophilia.EBI AstraZeneca
23927973 41 Discovery of nonbenzamidine factor VIIa inhibitors using a biaryl acid scaffold.EBI Bristol-Myers Squibb Research& Development
23602442 28 Discovery of diarylurea P2Y(1) antagonists with improved aqueous solubility.EBI Bristol-Myers Squibb
23586812 38 Development of a selective peptide macrocycle inhibitor of coagulation factor XII toward the generation of a safe antithrombotic therapy.EBI Ecole Polytechnique F�d�rale de Lausanne EPFL
23451707 23 Discovery of allosteric modulators of factor XIa by targeting hydrophobic domains adjacent to its heparin-binding site.EBI Virginia Commonwealth University
23316863 1 Sulfated pentagalloylglucoside is a potent, allosteric, and selective inhibitor of factor XIa.EBI Virginia Commonwealth University
23294255 114 Development of new cyclic plasmin inhibitors with excellent potency and selectivity.EBI Philipps University Marburg
16644215 52 Design and synthesis of selective keto-1,2,4-oxadiazole-based tryptase inhibitors.EBI Celera Genomics
22770607 54 Potent direct inhibitors of factor Xa based on the tetrahydroisoquinoline scaffold.EBI Virginia Commonwealth University
19715320 87 Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation.EBI University of Florida
18053726 364 Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality.EBI Johnson& Johnson Pharmaceutical Research& Development
18054227 45 Structure-activity relationship and pharmacokinetic profile of 5-ketopyrazole factor Xa inhibitors.EBI Bristol-Myers Squibb Research and Development
17588746 103 SAR and X-ray structures of enantiopure 1,2-cis-(1R,2S)-cyclopentyldiamine and cyclohexyldiamine derivatives as inhibitors of coagulation Factor Xa.EBI Bristol-Myers Squibb Company
16876411 17 Synthesis and in vitro biological evaluation of aryl boronic acids as potential inhibitors of factor XIa.EBI Daiichi Asubio Medical Research Laboratories, LLC
12270173 23 Targeting thrombin and factor VIIa: design, synthesis, and inhibitory activity of functionally relevant indolizidinones.EBI Universit£ de Montr£al
22041058 44 Arylsulfonamidopiperidone derivatives as a novel class of factor Xa inhibitors.EBI Bristol-Myers Squibb Company
21035339 16 Design and synthesis of macrocyclic indoles targeting blood coagulation cascade Factor XIa.EBI Université de Montréal
20650636 118 Discovery of a factor Xa inhibitor (3R,4R)-1-(2,2-difluoro-ethyl)-pyrrolidine-3,4-dicarboxylic acid 3-[(5-chloro-pyridin-2-yl)-amide] 4-[[2-fluoro-4-(2-oxo-2H-pyridin-1-yl)-phenyl]-amide] as a clinical candidate.EBI F. Hoffmann-La Roche Ltd
20405925 5 Multiple toxin production in the cyanobacterium microcystis: isolation of the toxic protease inhibitor cyanopeptolin 1020.EBI University of Basel
18674905 58 Factor VIIa inhibitors: target hopping in the serine protease family using X-ray structure determination.EBI Chugai Pharmaceutical Co., Ltd
18510371 2 Clavatadine A, a natural product with selective recognition and irreversible inhibition of factor XIa.EBI Griffith University
17643988 92 Enantiopure five-membered cyclicdiamine derivatives as potent and selective inhibitors of factor Xa. Improving in vitro metabolic stability via core modifications.EBI Bristol-Myers Squibb Company
16524727 25 Synthesis, SAR exploration, and X-ray crystal structures of factor XIa inhibitors containing an alpha-ketothiazole arginine.EBI Daiichi Asubio Medical Research Laboratories, LLC
24090423 13 Identification and structure-activity relationship study of carvacrol derivatives as Mycobacterium tuberculosis chorismate mutase inhibitors.BDB Birla Institute of Technology & Science-Pilani
 18 Novel multi-targeted agents for Alzheimer's disease: Synthesis, biological evaluation, and molecular modeling of novel 2-[4-(4-substitutedpiperazin-1-yl)phenyl]benzimidazolesBDB Hacettepe University
15449728 11 Design and synthesis of indole and tetrahydroisoquinoline hydantoin derivatives as human chymase inhibitors.BDB Université de Tours
15499999 35 Benzolamide is not a membrane-impermeant carbonic anhydrase inhibitor.BDB Università degli Studi di Firenze
16407991 13 Activity-based probes that target diverse cysteine protease families.BDB Stanford University
19848404 44 Discovery of potent and selective inhibitors of the mammalian target of rapamycin (mTOR) kinase.BDB Wyeth Research
19678708 28 Design, synthesis, and structure-activity relationships of aminopyridine N-oxides, a novel scaffold for the potent and selective inhibition of p38 mitogen activated protein kinase.BDB Almirall Research Center
18178084 24 Carbamate-appended N-alkylsulfonamides as inhibitors of gamma-secretase.BDB Bristol-Myers Squibb Company
19243938 3 Design, synthesis, and evaluation of peptidomimetics containing Freidinger lactams as STAT3 inhibitors.BDB University of Michigan at Ann Arbor
18783202 16 Identification of BRAF inhibitors through in silico screening.BDB University of Pennsylvania
18260617 131 3-Amino-benzo[d]isoxazoles as Novel Multitargeted Inhibitors of Receptor Tyrosine Kinases.BDB Abbott Laboratories
18020435 55 4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer.BDB Vernalis (R&D) Ltd
16386422 40 Discovery and SAR study of novel dihydroquinoline containing glucocorticoid receptor ligands.BDB Boehringer Ingelheim Pharmaceuticals Inc.
17350258 27 Lead optimization of methionine aminopeptidase-2 (MetAP2) inhibitors containing sulfonamides of 5,6-disubstituted anthranilic acids.BDB Abbott Laboratories
12954329 8 The structure of JNK3 in complex with small molecule inhibitors: structural basis for potency and selectivity.BDB Merck Research Laboratories
15482920 11 Isoxazole carboxylic acids as protein tyrosine phosphatase 1B (PTP1B) inhibitors.BDB Abbott Laboratories
12747781 29 Discovery and structure-activity relationship of oxalylarylaminobenzoic acids as inhibitors of protein tyrosine phosphatase 1B.BDB Abbott Laboratories